A comparison of relative-efficacy estimate(s) derived from both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons.  Cassidy O, Harte M, Trela-Larsen L, Walsh C, White A, McCullagh L, Leahy J., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023, pS1098-3015(23)03061-9 Journal Article, 2023 DOI

Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Cahir C, Curran C, Walsh C, Hickey A, Brannigan R, Kirke C, Williams D, Bennett K. Front. Pharmacol., 13 (2023). https://doi.org/10.3389/fphar.2022.1029067

The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review. Croke, A., Cardwell, K., Clyne B, Moriarty F, McCullagh L, Smith S M.  BMC Prim. Care 24, 41 (2023). https://doi.org/10.1186/s12875-022-01952-z

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L & Barry M (2023)   Journal of Market Access & Health Policy, 11:1, DOI: 10.1080/20016689.2023.2166375

Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Cochrane Database of Systematic Reviews 2023: Issue 1. Art. No.: CD012974. DOI: http://10.1002/14651858.CD012974.pub2.